Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2025Current Cancer Drug Targets

Integrated Computational and Experimental Discovery of a Promising Xanthine Derivative with Anticancer Potential Targeting EGFR

View Full Paper
Ask AI
Bookmark
Share

Authors

EEEslam B. ElkaeedRYReda G. YousefHEHazem Elkady

Discussion

Loading...

Member takes

Overview

Experimental evaluation reveals potent anticancer activity of T-1-PA by targeting EGFR, suggesting therapeutic potential.

Key Points

  • T-1-PA demonstrated a potent inhibitory effect on EGFR with an IC₅₀ of 0.736 μM, promoting anticancer activity.
  • In vitro assays indicated T-1-PA effectively inhibited the proliferation of HepG2 and MCF7 cells, yielding IC₅₀ values of 0.88 μM and 1.13 μM, respectively.
  • Computational analyses, including molecular docking and ADMET profiling, confirmed T-1-PA's strong binding affinity and favorable drug-like properties.
  • Induction of apoptosis and cell cycle arrest in HepG2 cells through EGFR inhibition suggests T-1-PA's significant therapeutic promise.

Cite This Study

Elkaeed et al. (2025) studied this question.

synapsesocial.com/papers/68e02f40f0e39f13e7fa2879https://doi.org/10.2174/0115680096363027250731042338
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1New Theobromine Apoptotic Analogue with Anticancer Potential Targeting the EGFR Protein: Computational and <i>In Vitro</i> Studies2024 · 7 citations
  2. 2In Silico Prediction of EGFR Inhibitors from Thiophene Derivatives2024
  3. 3Computational repurposing of 1,2,4-triazole-based Schiff bases as anticancer candidates: target-specific docking, DFT reactivity descriptors, and ADMET profiling2026
  4. 4Structure-Guided Design of 2-Amino-4-Phenylthiazole Derivatives Targeting EGFR: DFT Insights and Molecular Docking Evaluation2025
  5. 5Synthesis, Cytotoxicity Evaluation, and Molecular Dynamics of 4-Thiazolidinone Derivatives: A Potential Path to EGFR-Targeted Anticancer Therapy2025 · 1 citations